Effect of Blue Light Emitting Diode Therapy on Recurrent Vulvovaginal Candidiasis: A Randomized Assessor-Blinded Controlled Trial
Objective
Vulvovaginal Candidiasis (VVC) is a common genital infection in women and requires effective non-drug therapies. This study aimed to investigate the effect of blue light emitting diode (LED) therapy as an alternative treatment for recurrent VVC due to its proven antimicrobial properties. LED therapy is safe and non-invasive, making it a promising option for sensitive tissue applications.
Materials and Methods
60 women with confirmed VVC were recruited for this randomized controlled trial. They were divided into two groups: Group A received standard antifungal treatment, while Group B received the same antifungal treatment along with blue LED therapy directed at the vagina and vulva. Candida count and vaginal pH were assessed at baseline and one week after treatment.
Results
Group B showed a significantly greater reduction in Candida count compared to Group A. However, there was no significant difference in vaginal pH between the groups.
Conclusion
Blue LED therapy effectively reduces Candida count in women with recurrent VVC without affecting vaginal pH, demonstrating its safety and efficacy as a treatment modality.
PMID: 39223951 | DOI: 10.1002/pri.2129
Clinical Trials and Practical Solutions
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into an easily accessible knowledge base for clinicians.
Value in Healthcare Environment
Streamlining operations is crucial in today’s healthcare environment. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By using AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper routines. Learn more about how we can help at aidevmd.com.
